Last A$62.42 AUD
Change Today +0.32 / 0.52%
Volume 100.9K
COH On Other Exchanges
Symbol
Exchange
OTC US
Munich
OTC US
As of 2:11 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

cochlear ltd (COH) Snapshot

Open
A$61.60
Previous Close
A$62.10
Day High
A$62.79
Day Low
A$61.47
52 Week High
07/15/13 - A$64.24
52 Week Low
02/11/14 - A$51.79
Market Cap
3.6B
Average Volume 10 Days
182.0K
EPS TTM
A$1.34
Shares Outstanding
57.1M
EX-Date
02/28/14
P/E TM
46.8x
Dividend
A$2.70
Dividend Yield
4.33%
Current Stock Chart for COCHLEAR LTD (COH)

Related News

No related news articles were found.

cochlear ltd (COH) Related Businessweek News

View More BusinessWeek News

cochlear ltd (COH) Details

Cochlear Limited provides implantable hearing solutions. It offers the Cochlear Nucleus range of cochlear implant systems; Baha bone conduction implants for treating conductive hearing loss, mixed hearing loss, and single-sided deafness; bone anchored prosthetics, such as the Cochlear Vistafix bone-anchored facial prosthetic solution to enhance the attachment and cosmetic outcome of facial prostheses; and support services. The company provides its products directly, as well as through distributors and agents in the United States, Canada, and Latin America; Europe, the Middle East, and Africa; and Australasia and Asia. Cochlear Limited is headquartered in Macquarie University, Australia.

cochlear ltd (COH) Top Compensated Officers

Chief Executive Officer, President, Executive...
Total Annual Compensation: A$2.1M
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$676.5K
President of Asia Pacific Region
Total Annual Compensation: A$767.0K
President of Americas Region
Total Annual Compensation: A$673.8K
President of European Region
Total Annual Compensation: A$627.5K
Compensation as of Fiscal Year 2013.

cochlear ltd (COH) Key Developments

Cochlear Limited Receives US Food and Drug Administration Approval of the Aqua+ Accessory

Cochlear Limited announced that the US Food and Drug Administration (FDA) has approved the Aqua+ accessory, the only waterproof behind-the-ear solution for cochlear implant recipients on the market. The Aqua+ is a form-fitting, easy-to-use, versatile accessory that allows Cochlear(TM) Nucleus(R) 5 and Nucleus 6 Implant recipients to swim underwater for up to two hours. The new Aqua+ gives recipients the ability to swim while wearing their sound processor behind the ear. Its flexible, watertight sleeve simply fits over their sound processor behind the ear, so they don't have to find other places to secure their sound processor, like a swimsuit. A specially-designed waterproof coil then connects to the sound processor within the sleeve. While the Nucleus 5 and Nucleus 6 Sound Processors already have a high water resistance rating, the Aqua+ provides added confidence with its IP68 water resistance rating. It is safe to use in all types of water including chlorinated pools, fresh water lakes and rivers, saltwater oceans and pools, and soapy water. Additionally, the Aqua+ is a reusable solution allowing recipients to use the form-fitting sleeve numerous times without having to replace it. The Aqua+ Kit, which consists of all the necessary parts that recipients will need, can be ordered from the Cochlear Americas store beginning May 2, 2014. All Nucleus 5 and Nucleus 6 Cochlear Implant recipients in the United States and Canada are eligible to order the Aqua.

Cochlear Limited Announce FDA Approves Cochlear Nucleus Hybrid for Sale in USA

Cochlear Limited announced that the US Food and Drug Administration (FDA) approved the Cochlear Nucleus Hybrid L24 Cochlear Implant System for commercial release. This follows the unanimous recommendation for approval by the FDA Advisory Panel as disclosed on November 11, 2013. This is a first of its kind system designed for the treatment of adults with severe to profound sensorineural hearing loss in the high frequencies, but who can still hear low-frequency sounds with or without a hearing aid. The Nucleus Hybrid System combines acoustic amplification of low frequencies with the electrical stimulation of high frequencies in one device. It is designed to deliver patients superior quality and clarity of sound in even the most difficult hearing situations, especially hearing in noisy environments.

Cochlear Ltd. Presents at Australian Investment Conference, Mar-11-2014 10:00 AM

Cochlear Ltd. Presents at Australian Investment Conference, Mar-11-2014 10:00 AM. Venue: London, United Kingdom. Speakers: Christopher Graham Roberts, Chief Executive Officer, President, Executive Director, Member of Technology & Innovation Committee and Member of Medical Science Committee.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COH:AU A$62.42 AUD +0.32

COH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
William Demant Holding A/S kr489.60 DKK +1.90
View Industry Companies
 

Industry Analysis

COH

Industry Average

Valuation COH Industry Range
Price/Earnings 49.4x
Price/Sales 5.1x
Price/Book 11.6x
Price/Cash Flow 49.4x
TEV/Sales 4.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COCHLEAR LTD, please visit www.cochlear.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.